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LETTER TO THE EDITOR
The  recent  Journal  of  General  Physiology  Perspectives 
(133:227–229, 245–262) deal with several key issues in 
TRPA1. The four informative papers (Bang and Hwang, 
2009; Caspani and Heppenstall, 2009; Kwan and Corey, 
2009; Latorre, 2009) provided a comprehensive review 
on the recent progress and remaining puzzles. Ample 
evidence suggests that the sensory function of TRPA1 is 
evolutionarily  conserved.  This  notion  is  further  sup-
ported by the fact that TRPA1 from several mammalian 
species (human, rat, and mouse) is activated by com-
mon ligands (a plethora of electrophylus) through a 
common mechanism (covalent modification). However, 
recent studies from us and others have revealed species-
specific activation or blockade of TRPA1 by many ligands. 
Here, we wish to raise the awareness of the species dif-
ference issue, which has been largely overlooked thus 
far, but will have a profound impact on TRPA1 research 
and drug development.
The first case of species difference between TRPA1 
orthologs was demonstrated by Klionsky et al. (2007). 
They reported the identification of several small mole-
cules that potently block human TRPA1 (Fig. 1 A). How-
ever, when tested against rat TRPA1, these compounds 
are either inactive (AMG2504 and AMG7160) or dem-
onstrate reverse pharmacology and function as activa-
tors of rat TRPA1 (AMG9090 and AMG5445) (Klionsky 
et al., 2007). From a high throughput screening, we iden-
tified dozens of structurally related, thioaminal-contain-
ing analogues that block human TRPA1 but activate rat 
TRPA1 (Chen et al., 2008) (e.g., CMP1-3; Fig. 1 A). Several 
lines of evidence indicate that these compounds inter-
act with channel proteins through covalent modification. 
First, they are electrophilic compounds that are predicted 
to be reactive to nucleophilic cysteine and lysine resi-
dues. Second, when tested in La antigen-based ALARM 
NMR and ALARM MS studies, CMP1 modifies surface-
exposed cysteines to form predicted adducts, confirm-
ing its chemical reactivity. Third, structural analogues 
with the reactive sulfur atom exhibit reactivity and effects 
on TRPA1, whereas close analogues without the reactive 
sulfur atom (e.g., CMP4 in Fig. 1 A) do not affect channel 
function. Finally, Cys-621 of human TRPA1 and Cys-622 
of rat TRPA1, residues important for allyl isothiocya-
nate modification, were found to be important for CMP1-
mediated effects. Therefore, thioaminals covalently 
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modify human and rat channels but produce opposite 
gating effects.
In addition to thioaminals, several nonreactive com-
pounds also demonstrate species-specific effects. Menthol 
activates mouse TRPA1 at low micromolar concentrations 
and blocks at higher concentration. However, menthol 
exhibits only an agonist effect on human TRPA1 across 
a range of concentrations (Xiao et al., 2008). Further-
more, caffeine was shown to activate mouse TRPA1 but 
suppresses human TRPA1 activity (Nagatomo and Kubo, 
2008). From high throughput screening and medicinal 
chemistry, we identified human TRPA1 antagonists from 
multiple structurally distinct chemical classes. When tested 
at rat TRPA1, only a small portion demonstrates consis-
tent inhibitory effects, whereas a majﾭority either has 
dramatic reduced potencies as antagonists (>10-fold) or 
functions as agonists of rat TRPA1. As more compounds 
are disclosed and evaluated in multiple species, we pre-
dict that the species difference for TRPA1 will likely be 
a prevalent issue.
What are the implications of the species difference? 
First, this has to be taken into consideration when study-
ing the physiological and pathological function of TRPA1. 
TRPA1 has been proposed to be a molecular integrator 
of various endogenous stimuli (e.g., noxious cold, brady-
kinin, 4-hydroxynonenal, and 15-dPGJ2) to mediate sen-
sation, pain, and neurogenic inflammation (Bang and 
Hwang, 2009). This conclusion has been mostly derived 
from in vitro experiments using one ortholog and from 
in vivo experiments using rats or mice (Bautista et al., 
2006; Kwan et al., 2006). It is tempting, of course, to ex-
tend these findings into human and other species. How-
ever, this practice may not have been adequately jﾭustified. 
One heavily disputed issue is the involvement of TRPA1 
in noxious cold sensation (Bang and Hwang, 2009; 
Caspani and Heppenstall, 2009; Kwan and Corey, 2009; 
Latorre, 2009). Although activation of heterologoulsy ex-
pressed mouse TRPA1 by noxious cold has been well es-
tablished (Story et al., 2003; Sawada et al., 2007; Karashima 
et al., 2009), human TRPA1 was not activated by noxious 
cold (Jordt et al., 2004). Whether this discrepancy is re-
sulted from genuine species difference or from difference 
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Currently, there is great interest in pursuing TRPA1 an-
tagonists for pain and other indications. Testing in pre-
clinical animal species, mandated by the FDA before 
any compound entry into human clinical trials, is an in-
dispensable part of drug development. Animal models 
are not only used to assess the intended efficacy and 
discover new indications, but also to expose any on-tar-
get and off-target adverse side effects. Rats and mice are 
the most widely used species for pain research and com-
pound assessment. Based on our experience and that of 
others, many antagonists of human TRPA1 have differ-
ent effects on rat and mice channels. These compounds, 
albeit of potential utility for humans, must be excluded 
from the drug development process because assessing 
them in conventional rat/mouse models will not lead to 
useful information. One strategy to address this prob-
lem is to use higher species such as monkey and chim-
panzee, which share high TRPA1 sequence homology 
with humans (97.1 and 99.7% identical, respectively). 
Therefore, monkey/chimpanzee may serve as faithful 
surrogate models for humans, but their practical usage 
is limited by the availability of pain models, low through-
put, and huge expenses. Alternatively, transgenic ani-
mals can be generated for compound assessment. In 
any case, species difference is a serious challenge and 
should be overcome with creative technologies and 
heavy investment.
Finally, the cloud of species-specific difference does 
have a silver lining. Compounds with drastically species-
specific  effects  (e.g.,  CMP1  and  menthol)  can  be 
valuable tools to study channel biophysics and struc-
ture–function relationship. Through the characteriza-
tion of rat and human TRPA1 chimeras, we identified 
residues in the upper portion of the S6 domains as criti-
cal determinants of the opposite gating by CMP1: Ala-
946 and Met-949 of rat TRPA1 determine channel 
activation by CMP1, whereas equivalent residues of 
human TRPA1, Ser-943, and Ile-946 determine channel 
block (Chen et al., 2008). Through a similar approach, 
mouse-human chimeras revealed the pore domain (S5-S6) 
as critical to menthol-mediated inhibition. In addition, 
chimeras between dTRPA1 and mammalian channels 
led to the identification of several S5 residues as impor-
tant to the menthol-mediated effects. Interestingly, 
some of the S5 and S6 residues were important for   
effects mediated by different ligands, including men-
thol, AP18, AMG5445, and CMP1 (Xiao et al., 2008). 
These  residues  may  form  a  universal  ligand-binding 
pocket. Alternatively, given the diverse structure and 
reactivity among these ligands, such residues may par-
ticipate in channel gating instead of direct ligand bind-
ing. These and future findings using species difference 
will provide novel insights into how TRPA1 respond 
to stimuli.
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in experimental conditions has not been settled. Of note, 
dTRPA1  (from  Drosophila  melanogaster)  is  activated  by 
heat, but not by cold or allyl isothiocyanate, indicating 
functional divergence during evolution (Viswanath et al., 
2003). Another observation worth noting is the relatively 
low sequence homology among mammalian channels. 
For example, human and rodent TRPA1 are 79% identi-
cal, compared with 94% for TRPM8, 86% for TRPV1, 
93% for TRPV3, and 95% for TRPV4, respectively. The 
high degree of sequence variation in TRPA1 may lead to 
different responses to endogenous ligands. In addition, 
the physiological function of TRPA1 can be shaped by 
metabolic mechanisms of ligands, temporal/spatial ex-
pression of the channel, signal transduction pathways, 
and  animal  physiology.  Such  parameters  can  vary  be-
tween species and should be considered when extrapo-
lating findings across species.
Second, the species difference presents significant prac-
tical challenges to drug development targeting TRPA1. 
Figure  1.  Compounds  with  species-specific  effects  on  TRPA1. 
(A) The electrophilic thioaminals (with a reactive sulfur atom la-
beled by an asterisk) block human TRPA1, but activate rat TRPA1 
(AMG9090, AMG5445, CMP1, CMP2, and CMP3) or have almost 
no effects (AMG7160 and AMG2504) (Klionsky et al., 2007; Chen 
et al., 2008). CMP4, with a sulfur-to-nitrogen substitution, is not 
reactive and has no effects on human or rat channel. (B) Men-
thol is an activator of mouse TRPA1 at low concentrations and 
a  blocker  at  high  concentrations;  but  it  only  activates  human 
TRPA1 (Xiao et al., 2008). Caffeine activates mouse TRPA1 but 
blocks human TRPA1 (Nagatomo and Kubo, 2008).  Chen and Kym 625
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